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Summary 
The pharmacokinetics of chondroitin sulfate (CS, Condrosulf ~, IBSA, Lugano, Switzerland) were investigated in
rats and in healthy volunteers using CS tritiated at the reducing end and CS labeled withlZlI or 99mTc respectively. 
A rapid absorption of orally administered CS is observed in rats and in humans when the drug is dissolved in water. 
Lower and delayed absorption is observed when CS is administered in gastroresistant capsules. The absolute 
bio-availability is 15 and 12% for rats and humans respectively. The CS shows a tropism for cartilagineous ti sues in 
rats and for knee tissues in humans as demonstrated byscintigraphic analysis with 99mTc-CS. Monomers, oligo and 
polysaccharides produced by enzymatic hydrolysis of CS appear in the blood and tissues together with native CS. The 
effects of partially depolymerized (m.m. 3 to 15 kD) and desulfated fractions on human leukocytes were investigated. 
CS and its fractions inhibit the directional chemotaxis nduced by zymosan-activated s rum, are able to decrease the 
phagocytosis and the release of lysozyme induced by zymosan and to protect the plasma membrane from oxygen reactive 
species. In rats the oral administration f CS significantly decreases granuloma formation due to sponge implants and 
cell migration and lysosomal enzyme release in carrageenan pleurisy. Compared with nonsteroidal nti-inflammatory 
drugs (indomethacin, ibuprofen), CS appears to be more effective on cellular events of inflammation than on edema 
formation. It is noteworthy that CS is devoid of dangerous effects on the stomach, platelets and kidneys. In synovial 
fluid of patients requiring joint aspiration, treated orally for 10 days with CS (800 mg/day) the hyaluronate 
concentration a d the intrinsic viscosity significantly increased, while collagenolytic activity, phospholipase A2and 
N-acetylglucosaminidase (NAG) decreased. 
These results give an insight into the mechanism of the anti-inflammatory and chondroprotective actions 
demonstrated bythis drug in a number of clinical trials in patients with osteoarthritis. 
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Int roduct ion 
MANY clinical studies demonstrate he therapeutic 
effects of orally administered chondroitin sulfate 
(CS, Condrosulf ~, IBSA, Lugano, Switzerland) on 
osteoarthritic patients with improvement ofarticu- 
lar functions and reduction of pain [1-3]. However, 
some aspects of the pharmacokinetics of orally 
administered CS and of the mechanisms of its 
anti-inflammatory and chondroprotective activi- 
ties require further investigation. We have studied 
the tissue distribution and the pharmacokinetics 
of labeled CS in rats, the anti-inflammatory 
activity in experimental animals and human 
leukocytes, the pharmacokinetics of oral adminis- 
tration of the labeled drug in humans and its effect 
on some biochemical parameters of synovial fluid 
in osteoarthritic patients. 
Supplement sponsored by IBSA (Switzerland)/Laboratoires 
GENEVRIER (France). 
Materials and Methods 
MATERIALS 
3H-sodium borohydride, 3H-acetic anhydride, 
3H-arachidonate-labeled Escherichia coli suspen- 
sion and tritiated water were from NEN DuPont 
(Milan, Italy). 131I and 99mTc were from Sorin 
(Saluggia, Italy). The CS used in this experimental 
work was a mixture of chondroitin 4-sulfate (50%) 
and chondroitin 6-sulfate (50%) with an average 
molecular mass of 16 kDa, an SO3H/COOH ratio 
near to 1, devoid of anticoagulant activity. All 
chemicals were of analytical grade. 
METHODS 
The USA National Research Council's guide was 
followed for all research with animals. The ethical 
guide lines of the revised Declaration of Helsinki 
were followed for all research on healthy volun- 
teers or patients. 
CS was labeled at its reducing end using 
tritiated sodium borohydride [4]. The tritiated 
molecule (80~Ci/kg) was administered to rats 
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(240-260 g) by the intravenous (i.v.) (3.2 mg/kg) or 
oral (16 mg/kg) route. Plasma, urine and feces were 
collected at intervals, and the rats were sacrificed 
after 6 and 24 h for the collection of tissues and 
organs. After homogenization and evaluation of 
the total radioactivity the tissue samples were 
chromatographed on a Biogel P-100 (1.5• 
column to evaluate the radioactivity with molecu- 
lar mass (m.m.) similar to that of the administered 
drug which was utilized to calculate the pg of 
exogenous CS present in the samples. 
CS was also labeled with one residue of 
hydroxyphenyl propionate per 70 residues of chain 
sugars. The molecule was then iodinated with 131I 
[5]. The labeled and unlabeled CS had similar 
biological and chemical properties. The labeled CS 
(0.8 g in water; 50 ~Ci) was administered per os to 
four healthy volunteers. Four volunteers received 
25 mg of CS (50 pCi) in gastroresistant capsules. 
The plasma radioactivity was fractionated on the 
basis of m.m. by gel filtration (Biogel P-100, 
1.5 • 80 cm). 
SPECT analyses of lower limbs as a function of 
the time after intravenous administration of 
CS-labeled 99mTc to two healthy volunteers were 
also carried out [6]. 
A foot edema test was carried out in rats using 
1% carrageenan solution [7]. The method de- 
scribed by P. J. Bailey for rats was followed for the 
sponge implant test (including enzyme determi- 
nation) [8]. For the pleurisy test carrageenan 
(0.5 rag) was injected into rats [9]. CS fractions of 
molecular mass (m.m.) ranging from 3 to 24 kDa 
were obtained with partial enzymatic hydrolysis by 
hyaluronidase followed by fractionation on a gel 
filtration column. Peripheral blood neutrophils 
were obtained from blood donors. Under agarose 
chemotaxis, phagocytosis, lysozyme and membrane 
protection were investigated as reported [10, 11, 12 
and 13, respectively]. 
PATIENTS'  TREATMENT 
Twenty-four osteo-arthritic patients needing 
joint aspiration were investigated. In 12 patients 
(nine females), the synovial fluid parameters were 
determined before treatment and after 0.8 g of CS 
once a day for 10 days. Twelve patients (eight 
females) received the placebo (control sample). The 
mean age, body weight and height + S.D. of the two 
groups of patients were 69.3 _+ 7.8 years, 64.0 + 9.1 
years; 57.4_+ 6.1kg, 55.7_+ 5.Skg and 162.5 _+ 
9.4 cm, 164.2 _+ 8.9 cm, respectively. The synovial 
fluids of all the patients were clear or straw- 
colored, with high viscosity, strong mucine 
clotting and without fibrin clotting. The osteo- 
arthritic patients received neither steroidal nor 
nonsteroidal anti-inflammatory drugs for 20 days 
before and during treatment. Neither had they 
received previous intra-articular injections. Pro- 
tein concentrations were determined with Fotin 
phenol reagent according to Lowry et al. [14]. 
Hyaluronate concentration was determined by the 
Tengblad method [15]. For the assay of col- 
lagenolytic activity exogenous (3H)-bovine type II 
collagen was used [16]. Phospholipase A2 (PLA@ 
activity was tested as described by Pruzanski et al. 
[17]. The activity is expressed as units/ml, 
where one unit of PLA2 activity is defined as 
the release of 1% of the radioactivity incorporated 
into Escherichia coli under the assay conditions 
described, and was equal to the hydrolysis of 
90 pmol Escherichia coli phospholipid in 30 min at 
37~ N-acetylglucosaminidase (NAG) activity 
was assayed using p-nitrophenyl N-acetyl-~-D- 
glucosaminide as substrate [18]. 
To measure the intrinsic viscosity, the synovial 
fluids were dialyzed against a solution containing 
l0 mM sodium phosphate buffer pH 7.3 and 0.2 m. 
The viscosity was determined with a 2.0ml 
Ostwald viscosimeter with a capillary diameter of 
0.5 mm at a water flow time of 200 seconds in a 
water bath at a constant temperature of 
20 _+ 0.05~ as described by Kragh [19]. Appropri- 
ate dilution, depending on the hyaluronate content 
of the synovial fluids, was made with the buffer 
described above. The intrinsic viscosity was 
calculated following Sundblad [20]. 
STATISTICAL ANALYSIS 
Differences in experimental results were ana- 
lyzed by Student's t-test. Data are reported as 
mean _+ standard deviation (S.D.). P values less 
than 0.05 were considered as significant. 
Resu l ts  
Table I reports the distribution in urine, feces 
and tissues calculated for CS and CS together with 
its metabolites (M) 6 h after administration. We 
found that 53% and 19% of the administered drug 
is excreted, respectively, by the kidneys in the first 
24 h after i.v. and oral administration. In Table I 
the distribution in some tissues 6 h after adminis- 
tration is also reported. When tissue radioactivity 
is fractionated on the basis of m.m. we observed 
that tissue radioactivity after i.v. injection is 
mainly due to CS radioactivity, while after oral 
administration low m.m. radioactivity due to 
oligosaccharides, monomer and tritiated water is 
higher than CS radioactivity. However, with a 
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Table I 
Distribution and tissue concentration of chondroitin sulfate and its metabolites 6 h 
after administration to rats* 
Intravenous Oral 
CS CS + M CS CS + M 
Distribution 
Tissues + blood 280 + 30 350 + 30 300 • 40 1830 _+ 200 
Urine + bladder content 230 + 20 380 • 40 90 _+ 10 370 __ 40 
Feces + intest, content - 20 + 10 - 1560 + 160 
Concentration 
Stomach 1.6 • 0.5 1.7 • 0.4 3.8 • 1.6 12.0 • 3.7 
Small intestine 1.2 • 0.3 1.6 • 0.4 3.4 • 1.6 13.3 • 4.8 
Liver 3.0 + 0.9 6.2 + 1.6 2.0 + 0.8 18.1 • 6.1 
Kidneys 2.9 + 0.7 53 + 1.5 3.1 • 0.9 18.5 • 4.8 
Brain 0.2 + 0.1 0.5 + 0.3 0.2 + 0.1 2.5 • 0.9 
Art icular  cart i lage 3.6 + 0.8 4.2 + 1.4 3.3 • 0.9 11.5 • 4.1 
Synovial fluid 3.4 • 0.9 3.6 • 1.0 3.2 • 1.0 10.7 • 3.5 
Blood 1.9 • 0.8 2.3 • 0.7 2.1 • 0.7 8.4 • 3.2 
The reported values are the means • S.D.; n= 10. 
*The amount of chondroitin sulfate (CS) and of chondroitin sulfate plus its metabolites 
(CS + M) are reported in I~g/g for tissues and in pg/ml for biological fluids. The amounts of 
tritiated chondroitin sulfate administered to rats were 3.2 mg/kg by the intravenous route 
or 16 mg/kg by the oral route. 
dose ra t io  of  1:5 between i.v. and  ora l  admin is -  
t ra t ion ,  s imi la r  quant i t ies  of  CS are  observed  in 
b lood,  synov ia ,  a r t i cu la r  car t i l age  and  many other  
o rgans .  D i f fe rences  are  observed  in the  in tes t ina l  
t rac t  due to the  d i f ferent  routes  of  admin is t ra t ion  
used.  
The h igh  content  of  labe led  CS observed  in the  
synov ia l  f lu id and  car t i lage  due to the  t rop ism of  
admin is tered  CS for these  t i ssues  is notewor thy .  
In  Tab le  II, the  pharmacok inet i c  parameters  
determined f rom to ta l  rad ioact iv i ty  va lues  corre-  
spond ing  to CS p lus  i ts  metabo l i tes  are  repor ted .  I t  
appears  that  CS is rap id ly  adsorbed  in the  
gast ro - in tes t ina l  t rac t .  F rom p lasma area  under  
the  curve  (AUC)  va lues  vs t iming,  and  from 
ur inary  e l iminat ion  of  the  drug,  the  abso lu te  
b io -ava i lab i l i ty  tu rns  out  to be 15% by ora l  
admin is t ra t ion .  
F igure  1 repor ts  the  p lasma leve ls  of  CS in 
humans  obta ined  a f ter  f rac t ionat ion  of  to ta l  
rad ioact iv i ty  on gel  co lumns.  A rap id  increase  is 
observed  af ter  admin is t ra t ion  in water  w i th  a 
max imum at  I h. The rad ioact iv i ty  is p resent  to a 
measurab le  extent  a f ter  24 h. A f te r  admin is t ra t ion  
in gast rores i s tant  capsu les  the  CS peak  is observed  
at  4h .  
The p lasma rad ioact iv i ty  wh ich  appears  on a gel  
f i l t ra t ion  co lumn in the  same pos i t ion  of  labe led  
CS is about  60-70%, wh i le  about  30~40% of to ta l  
rad ioact iv i ty  is observed  in the  same pos i t ion  of  
low m.m. degradat ion  products  and  iodide.  S imi la r  
resu l t s  are  obta ined  by the  f rac t ionat ion  of  p lasma 
af ter  extens ive  papa in  d igest ion  of prote ins .  
Tab le  I I I  repor ts  some k inet i c  parameters  of  ora l  
admin is t ra t ion  of  131I-labeled CS. The va lues  are  
re fer red  to 0.8 g of  admin is tered  drug.  
Table II 
Pharmacokinetic parameters of chondroitin sulfate (CS) and its metabolites (M) after administration of the drug to rats 
Pharmacokinet ic  parameters 
Intravenous Oral 
CS CS + M CS CS + M 
Time peak (min) 
Peak concentrat ion (llg/ml) 
tl/2 distr ibution (min) 14.1 _+ 4.3 
tl/2 el imination (rain) 182 + 24 
Volume of central compartment (ml) 21.4 _+ 3.8 
Volume of tissue compartment (ml) 82.1 • 27.0 
AUC0-1440 rain administered substance (pg.ml/min) 32.8 _+ 4.5 
46 _+ 15 635 _+ 91 
- 2.5 _+ 0.5 8.9 _+ 0.9 
297 __ 88 
38.4 _+ 9.5 
129 _+ 48.3 
45.7 • 5.2 28.4 _ 5.1 174.6 _+ 23.0 
The reported values are the means • S.D.; n= 10. 
CS = chondroitin sulfate; CS + M = chondroitin sulfate and its metabolites. 
AUC = area under the curve. 
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FIG. 1. Chondroitin sulfate concentration i plasma fter 
administration to humans. The data reported are the 
means of plasma values of four healthy volunteers who 
received chondroitin sulfate in water (m) or in gastro- 
resistant capsules ([~). In both groups the concentration 
values are referred to 800 mg administration. 
Radioact iv i ty  observed in urine consists of low 
m.m. der ivat ives or iodide. However,  high m.m. CS 
and depolymerized CS der ivat ives are present in 
urine col lected in the first hours. Total  radioac- 
t ivity excreted in urine after 72 h is about  19% of 
the administered CS for administrat ion in water  
and 14% for administrat ion in gastrores istant  
capsules. 
About 90% of administered radioact iv i ty  is 
recovered in urine and feces after 72 h with both 
administrat ions.  
From plasmatic and ur inary values, it appears 
that  the bio-avai labi l i ty as high m.m. CS is about  
12% when the drug is administered in water, which 
is the usual administrat ion route. 
SPECT analysis of lower l imbs as a funct ion of 
t ime after intravenous administrat ion of 99mTc as 
sodium pertechnate or CS labeled with 99'nTc shows 
that  radioact iv i ty  is h igher during the first 40 min 
in the thigh and in the calf  as compared with knee 
tissues. After this t ime the radioact iv i ty  progress- 
ively increases in the knee tissues and becomes 
much higher than in the adjacent  issues as can be 
seen in Fig. 2 in which the radioact iv i ty  of 99mTc 
sodium pertechnate and of CS labeled with 99mTc as 
well their  difference is reported after 2 h from 
administrat ion.  
Table IV reports some pharmacologica l  
activit ies of CS in rats compared with the anti- 
in f lammatory propert ies of ibuprofen and in- 
domethacin.  It appears that  CS administered per os 
has an ant i - inf lammatory act iv i ty comparable to 
that  of ibuprofen and indomethacin on the 
development of granu loma due to sponge implants. 
The drug act iv i ty has been measured after 10 h 
from the implant  by the determinat ion of myeloper- 
oxidase (MPO) act iv i ty to evaluate the anti-inflam- 
matory  act iv i ty on po lymorphonuclear  neutrophi l  
(PMN) inf i l trat ion of sponges and after 12 days by 
determinat ion of NAG act iv ity to evaluate macro- 
phage infi ltration. The activit ies in the untreated 
controls are 173.7 _+ 35.0 and 18.4 _+ 5.3 pmol/h/ 
sponge for MPO and NAG, respectively. A 
comparable act iv i ty is also observed in leukocyte 
migrat ion and N-acety lg lucosaminidase release in 
car rageenan pleurisy determined 3 h after car- 
rageenan administrat ion.  The leukocyte and the 
NAG act iv i ty in untreated controls were 
95.8 _+ 19.1 • 10 ~ and 12.3 _+ 1.8 U/l, respectively. In 
the development of edema, CS is also active; 
however,  its act iv ity appears to be lower than that  
of ibuprofen and indomethacin.  In the untreated 
controls the percentage increase of paw volume is 
38.5 _+ 3.2. 
Some activit ies of CS fract ions on human 
leukocytes are reported in Table V. CS fract ions 
between 3 and 24kDa and 12kDa part ia l ly  
desulfated are devoid of chemokinet ic  and chemo- 
tact ic activit ies (data not reported) and have a 
signif icant ant ichemotact ic  act iv ity on leukocytes 
using human serum act ivated by zymosan as 
Table III 
Some kinetic parameters of chondroitin sulfate (CS) and its metabolites (M) after 
the drug to humans 
oral administration of 
t . . . .  C . . . . .  AUC tl/2 Vd 
Administration h ~g/ml pg.h/ml h 1 
In water 
CS 1.0 • 0.3 6.6 + 0.7 86.6 • 12.6 8.6 • 0.7 30.3 • 3.5 
CS + M 0.5 • 0.2 9.4 • 1.1 121.1 • 20.2 8.3 • 0.9 29.7 • 4.0 
In gastroresistant capsules 
CS 4.0 • 1.0" 2.4 • 0.5* 47.0 • 5.5* 9.4 • 1.0 31.4 • 3.9 
CS + M 4.0 • 1.1" 3.8 + 0.6* 71.7 • 8.2* 8.7 • 1.1 32.0 • 4.3 
The reported values are the means +_ S.D. and are referred to 800 mg administration; u=4; *P < 0.05 vs the 
respective value. 
CS = chondroitin sulfate; CS + M = chondroitinsulfate and its metabolites. 
AUC = area under the curve. 
Cmax ~- maximum drug concentration i  plasma fter a single dose. 
tm~x =time required to reach C .... 
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FIG. 2. (A) SPECT analysis of lower limbs 2 h after intravenous administration of99mTc sodium pertechnate. (B) SPECT 
analysis of lower limbs 2 h after intravenous administration of CS labeled with 99mTc. (C) Difference between B 
and A. 
chemoattractant. All the fractions decrease phago- 
cytosis and lysozyme release and protect the 
plasma membrane from damage by reactive oxygen 
species. All fractions show their activity between 
1 to 20 ~g/ml, and this activity is dose-dependent. 
The effect on some synovial fluid parameters of 
10 days treatment with CS (800 mg/day) by the oral 
route on osteo-arthritic patients who needed joint 
aspiration is reported in Table VI. The concen- 
tration of hyaluronate, as well as its m.m. 
evaluated by viscosity, significantly increased in 
the synovial fluid of treated patients while protein 
concentration does not change. Collagenolytic, 
phospholipase A2, and NAG activities are signifi- 
cantly decreased after 10 days of CS treatment. 
Discuss ion  
The absorption of a glycosaminoglycan drug by the 
oral route could depend on the length of poly- 
saccharide chains, on the charge density and the 
presence of clusters with a high number of sulfate 
groups and on the kind of ions with which the 
charged groups of the drug have been neutralized. 
In preceding papers, it has been shown that 
orally administered tritiated chondroitin sulfate is 
absorbed and is found in plasma as high, low and 
intermediate molecular weight metabolites 
[4, 21, 22]. Tritiated water derived from metaboliza- 
tion of tritiated chondroitin sulfate is also present. 
Absorbed radioactivity is distributed to the tissues 
and, in particular, to the liver, kidneys, synovial 
fluid and cartilage. We have fractionated the 
radioactive material by gel filtration columns and 
have calculated the chondroitin sulfate and its 
metabolites as a function of time from adminis- 
tration. It should be pointed out that tritiated 
chondroitin sulfate is labeled at the reducing end. 
The in vivo enzyme degradation of the polymer 
proceeds, step by step, from the non-reducing end 
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Table IV 
Anti-inflammatory activity of chondroitin sulfate (CS), ibuprofen and indomethacin orally administered to rats 
CS Ibuprofen Indomethacin 
200 mg/kg 50 mg/kg 5 mg/kg 
(%) (%) (%) 
Oedema formation (paw vol.) 
-by carrageenin 78.7 • 8.0* 54.0 _+ 5.4* 46.7 • 4.5* 
Granuloma formation 
~y sponge 
(a) myeloperoxidase activity (10 h) 
(b) N-acetyl glucosaminidase activity (12days) 
Carrageenan pleurisy 
Total leukocytes (number) 
N-acetylglucosaminidase 
62.5 • 5.4* 70.4 • 7.9* 66.9 + 5.8* 
53.6 i 6.3* 59.0 _+ 8.3* 61.0 • 7.2* 
73.4 _+ 6.3* 72.0 • 7.0* 74.1 _+ 7.9* 
72.5 • 8.3* 68.7 • 5.4* 76.0 _+ 8.0" 
The reported values are means _+ S.D.; n = 10. *P < 0.05 with respect to the controls. 
The absolute values of the controls are reported in the test. 
Myeloperoxidase and N-acetylglucosaminidase ctivities have been determined 10 hours and 12 days after sponge implant 
and are respectively proportional to the PMN and macrophages infiltration. 
CS = chondroitin sulfate. 
toward the reducing end. For this reason, even if 
enzymatic or chemical  f ragmentat ion of chon- 
droit in sulfate takes place inside the chain, the 
labeled reduced sugar at the end of the polymer 
chain of the administered tr i t iated chondroit in 
sulfate is mainta ined ur ing all the depolymeriza- 
t ion process. We have also observed (data not 
reported) that  only an i r re levant  part  (less than 
1%) of the radioact iv i ty  of chondroit in sulfate is 
released by exchange during 48 hours incubat ion 
in rat  plasma. For this reason the tr i t iated water  
that  is formed derives in the greater  part  from 
metabol izat ion of the reduced end sugars (e.g. 
xilitol, galact i to l  . . . .  ) only when these sugars are 
freed, since no enzymes are known at this moment  
which catalyze the re-oxidation of the sugars 
labeled at the reducing end of the glycosaminogly- 
can chains. 
After administrat ion of labeled chondroit in 
sulfate in water  by the oral route, the t ime peak of 
CS absorpt ion is observed at 46 and 60 min in rats 
and humans,  respectively. These values are similar 
to the peak t ime observed in humans in which only 
the high-molecular  weight species were deter- 
mined after oral administrat ion of unlabeled drug 
[21]. When CS is administered in gastrores istant  
capsules, the t ime peak is observed at 4 h and a 
lower quant i ty  of CS is absorbed. Our experiments 
clearly demonstrate that  CS is absorbed both at the 
gastr ic and the intest inal  level. We suggest that  
the high m.m. CS reaches the blood c irculat ion 
through the lymphat ic  system and the thoracic  
duct together  with the l ipoproteins and other 
macromolecules,  avoiding in this way the first 
hepatic passage. 
The AUC value and C .... are also comparable  in 
rats and humans when the radioact iv i ty  is frac- 
t ionated and the CS concentrat ion is determined. 
The radioact ive mater ia l  present in synovial  
fluid and in the cart i lage of rats is exogenous 
chondroit in sulfate and poly-ol igosaccharides and 
monomers derived from part ia l  or complete 
depolymerizat ion of the administered rug. The 
tropism of exogenous CS for art icu lar  t issues is 
also well documented by SPECT analysis of 
99mTc-CS administered to humans. 
Table V 
Some in vitro activities of chondroitin sulfate and its fractions on human leukocytes 
Chondroitin sulfate Antichemotactic Phagocytic activity Lysozyme 
fractions activity migration (%) release 
(molecular mass) (mm) (%) 
Membrane damage 
by reactive oxygen 
species (%) 
No addition 8.6 • 1.4 100 • 10 100 +_ 9 
A ( > 24 kDa) 6.3 +_ 1.3" 70 • 7* 61 _+ 6* 
B (20 kDa) 5.7 • 0.8* 65 • 10" 55 • 8* 
C (12 kDa) 4.9 • 0.7* 72 • 9* 55 • 11" 
D (6 kDa) 4.3 • 0.7* 68 • 5* 60 _+ 7* 
E (3 kDa) 4.5 + 0.6* 69 • 8* 63 _+ 5* 
CdS (12 kDa 50% desulfated) 5.3 + 0.8* 76 _+ 6* 59 • 9* 
100 • 8 
66 + 9* 
64 • 7* 
66 • 10" 
70 • 6* 
68 • 7* 
70 + 8* 
The reported values are means 4- S.D.; n = 6; *P < 0.05 with respect to the controls. 
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Table VI 
Synovial fluid parameters after chondroitin sulfate treatment of gonoarthrosic patients 
Patients Hyaluronate Proteins Leukocytes Collagenolytic PLA2 NAG 
mg/ml h] mg/ml 103/~1 activity nmol/min/ml U/L 
dpm/h/ml 
Treated (n = 12) 
Day0 1.8 • 0.7 43:9 • 5.6 31.3 • 5.2 2.4 _+ 1.5 1329 _+ 257 3.1 __ 0.7 36.7 _+ 5.3 
Day10 2.4 • 0.7* 49.2 _+ 4.5* 30.5 __ 3.9 1.9 + 1.5 935 • 197" 2.2 • 0.5* 24.3 • 3.1" 
Untreated (n = 12) 
Day0 1.7 • 0.9 42.7 _+ 6.1 34.2 • 4.8 2.3 • 1.3 1374 • 311 2.9 • 0.6 32.2 • 6.2 
Dayl0 1.9 • 0.7 44.5 _+ 5.0 33.7 _+ 5.7 2.4 • 1.4 1215 • 230 2.8 • 0.7 30.6 _+ 4.4 
The reported values are the means + S.D.; *P < 0.05 with respect to day 0. 
PLA~ = phospholipase A2. 
NAG = N-acetylglucosaminidase. 
The presence of exogenous chondroit in sulfate 
and its depolymerized der ivat ives in synovial  fluid 
and cart i lage is very important  in explaining the 
ant i - inf lammatory and chondroprotect ive effects of 
this drug. I t  is also very important  hat  the mainly 
CS depolymerized der ivat ives are active on 
leukocyte funct ions and protect  cell membranes.  
It  appears  that  CS is an effective anti- 
in f lammatory compound, a l though less act ive than 
indomethac in  and ibuprofen on the basis of the 
administered quantit ies. However,  CS is devoid of 
dangerous effects on stomach, platelets and 
kidneys, and its use may be mainta ined for years 
without  re levant  col lateral  effects. It  is note- 
worthy that  CS is more act ive on the cel lular 
component  of the inf lammatory process, while its 
act iv i ty is lower on the vascular  aspect. Anti- 
in f lammatory act iv i ty is confirmed by the modifi- 
cat ion of some biochemical  parameters  in the 
synovial  fluid of osteo-arthr i t ic  patients. 
In conclusion, a general  picture can be drawn 
from the data obta ined in exper imental  animals 
and in humans  on the metabol ic  fate of oral ly 
administered chondroi t in  sulfate. The drug is 
absorbed as high-molecular-mass polysacchar ide 
together  with low-molecular-mass polysacchar ide 
chains result ing from part ia l  depolymerizat ion 
and/or desulfation. 
We have also demonstrated that  the oral ly 
administered drug reaches synovial  fluid and 
cart i lage and modifies some pharmacologic  and 
biochemical  markers  in exper imental  animals and 
osteo-arthr i t ic  patients.  The therapeut ic  act iv ity of 
CS in osteoarthr i t is  may be due to at least three 
main mechanisms which have been demonstrated 
up to now: (1) the ant i - inf lammatory act iv i ty which 
is more evident on the cel lular aspect of the 
inf lammation and which is devoid of the col lateral  
effects of other ant i - inf lammatory nonsteroidal  
drugs; (2) the metabol ic  effects on the synthesis of 
hya luronate  and on the cart i lage proteoglycans; 
(3) the direct ant idegradat ive act ions which are 
real ized by the inhibit ion of some proteolyt ic 
activit ies (collagenase, elastase, proteogly- 
canase . . . .  ) and by the decrease of dangerous 
effects on matr ix  molecules determined by react ive 
oxygen species. 
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